肺癌筛查:美国癌症协会2023年指南更新
美国癌症协会更新2013年肺癌筛查指南,基于系统综述、模型评估和疾病负担数据,推荐50-80岁、吸烟≥20包年且目前吸烟或曾经吸烟的无症状个体每年进行低剂量CT肺癌筛查(强推荐,中等质量证据)。
要点
- 推荐50-80岁、吸烟≥20包年且目前或曾经吸烟的无症状个体每年低剂量CT筛查(强推荐,中等质量证据)。
- 开始筛查前应与合格健康专业人员共同决策讨论。
- 曾经吸烟者戒烟年数不作为开始或停止筛查的资格标准;目前吸烟者应接受戒烟咨询并连接戒烟资源。
核心结论
- 美国癌症协会推荐对50-80岁、吸烟≥20包年且目前吸烟或曾经吸烟的无症状个体每年进行低剂量CT肺癌筛查(强推荐,中等质量证据)。
- 50-80岁男女低剂量CT筛查与肺癌死亡减少相关,推断性证据支持对80岁以上健康状况良好的男女进行筛查。
研究设计与样本
- 美国癌症协会指南制定组基于美国预防服务工作组2021年肺癌筛查推荐更新所委托的系统综述、关于戒烟年数与肺癌风险关系的第二项系统综述、2021年后发表的文献、两个经癌症干预与监测建模网络验证的肺癌模型、一项流行病学与建模分析以及低剂量CT获益-辐射风险比的更新分析制定本指南。
- 指南制定组还审查了美国国家癌症研究所监测、流行病学和最终结果项目的疾病负担数据,推荐基于证据质量和关于获益与危害平衡的判断(纳入价值观与偏好)制定。
主要发现
- 指南制定组判断总体证据为中等质量且足以支持对符合资格标准的个体进行筛查的强推荐。
- 50-80岁男女低剂量CT筛查在多种研究设计中与肺癌死亡减少相关。
- 推断性证据支持对80岁以上健康状况良好的男女进行低剂量CT筛查。
关键数值与推荐
- 推荐50-80岁、目前吸烟或曾经吸烟且吸烟史≥20包年的无症状个体每年进行低剂量CT肺癌筛查(强推荐,中等质量证据)。
- 开始低剂量CT筛查前,个体应与合格健康专业人员共同决策讨论。
- 对于曾经吸烟者,戒烟年数不是开始或停止筛查的资格标准。
- 目前吸烟者应接受戒烟咨询并连接戒烟资源。
- 因合并症导致预期寿命明显受限的个体不应筛查。
临床怎么用
- 美国癌症协会推荐对50-80岁、吸烟≥20包年且目前或曾经吸烟的无症状个体每年进行低剂量CT肺癌筛查(强推荐,中等质量证据)。
- 开始筛查前应进行共同决策讨论;曾经吸烟者戒烟年数不作为开始或停止筛查的资格标准。
- 目前吸烟者应接受戒烟咨询并连接戒烟资源;因合并症导致预期寿命明显受限者不应筛查。
- 卫生保健提供者和肺癌高危成人应在低剂量CT筛查讨论中考虑这些推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer is the leading cause of mortality and person-years of life lost from cancer among US men and women. Early detection has been shown to be associated with reduced lung cancer mortality. Our objective was to update the American Cancer Society (ACS) 2013 lung cancer screening (LCS) guideline for adults at high risk for lung cancer. The guideline is intended to provide guidance for screening to health care providers and their patients who are at high risk for lung cancer due to a history of smoking. The ACS Guideline Development Group (GDG) utilized a systematic review of the LCS literature commissioned for the US Preventive Services Task Force 2021 LCS recommendation update; a second systematic review of lung cancer risk associated with years since quitting smoking (YSQ); literature published since 2021; two Cancer Intervention and Surveillance Modeling Network-validated lung cancer models to assess the benefits and harms of screening; an epidemiologic and modeling analysis examining the effect of YSQ and aging on lung cancer risk; and an updated analysis of benefit-to-radiation-risk ratios from LCS and follow-up examinations. The GDG also examined disease burden data from the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Formulation of recommendations was based on the quality of the evidence and judgment (incorporating values and preferences) about the balance of benefits and harms. The GDG judged that the overall evidence was moderate and sufficient to support a strong recommendation for screening individuals who meet the eligibility criteria. LCS in men and women aged 50-80 years is associated with a reduction in lung cancer deaths across a range of study designs, and inferential evidence supports LCS for men and women older than 80 years who are in good health. The ACS recommends annual LCS with low-dose computed tomography for asymptomatic individuals aged 50-80 years who currently smoke or formerly smoked and have a ≥20 pack-year smoking history (strong recommendation, moderate quality of evidence). Before the decision is made to initiate LCS, individuals should engage in a shared decision-making discussion with a qualified health professional. For individuals who formerly smoked, the number of YSQ is not an eligibility criterion to begin or to stop screening. Individuals who currently smoke should receive counseling to quit and be connected to cessation resources. Individuals with comorbid conditions that substantially limit life expectancy should not be screened. These recommendations should be considered by health care providers and adults at high risk for lung cancer in discussions about LCS. If fully implemented, these recommendations have a high likelihood of significantly reducing death and suffering from lung cancer in the United States.
引用
- Wolf AMD, Oeffinger KC, Shih TY, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society. CA Cancer J Clin. 2023. PMID: 37909877. doi:10.3322/caac.21811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。